Skip to main content
Journal cover image

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Publication ,  Journal Article
Davies, MJ; Aroda, VR; Collins, BS; Gabbay, RA; Green, J; Maruthur, NM; Rosas, SE; Del Prato, S; Mathieu, C; Mingrone, G; Rossing, P; Buse, JB ...
Published in: Diabetologia
December 2022

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycaemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional healthcare team providing diabetes care in the USA and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the healthcare system and physical activity behaviours including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Diabetologia

DOI

EISSN

1432-0428

Publication Date

December 2022

Volume

65

Issue

12

Start / End Page

1925 / 1966

Location

Germany

Related Subject Headings

  • United States
  • Sodium-Glucose Transporter 2 Inhibitors
  • Hypoglycemic Agents
  • Hyperglycemia
  • Humans
  • Glucagon-Like Peptide-1 Receptor
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 2
  • Consensus
  • Adult
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., … Buse, J. B. (2022). Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 65(12), 1925–1966. https://doi.org/10.1007/s00125-022-05787-2
Davies, Melanie J., Vanita R. Aroda, Billy S. Collins, Robert A. Gabbay, Jennifer Green, Nisa M. Maruthur, Sylvia E. Rosas, et al. “Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia 65, no. 12 (December 2022): 1925–66. https://doi.org/10.1007/s00125-022-05787-2.
Davies, Melanie J., et al. “Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia, vol. 65, no. 12, Dec. 2022, pp. 1925–66. Pubmed, doi:10.1007/s00125-022-05787-2.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022 Dec;65(12):1925–1966.
Journal cover image

Published In

Diabetologia

DOI

EISSN

1432-0428

Publication Date

December 2022

Volume

65

Issue

12

Start / End Page

1925 / 1966

Location

Germany

Related Subject Headings

  • United States
  • Sodium-Glucose Transporter 2 Inhibitors
  • Hypoglycemic Agents
  • Hyperglycemia
  • Humans
  • Glucagon-Like Peptide-1 Receptor
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 2
  • Consensus
  • Adult